Blog

Press Release

Press

Intra-Cellular Therapies Reports Second Quarter 2024 Financial Results, Provides Corporate Update and Raises 2024 CAPLYTA Sales Guidance

NEW YORK, Aug. 07, 2024 (GLOBE NEWSWIRE) — Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system (CNS) disorders, today announced its financial results for the second quarter ended June 30, 2024 and provided a corporate update. “We are very pleased with the strong performance of CAPLYTA during the second quarter and look forward to continued growth for the remainder of 2024,” said Dr. Sharon Mates, Chairman and CEO of Intra-Cellular Therapies. “Our team is also focused on preparing our sNDA for MDD for submission later this year and continues to advance our robust pipeline.” Second Quarter Financial…

Cybin

Press

Cybin to Participate in the Canaccord Genuity 44th Annual Growth Conference

Cybin Inc. (NYSE American:CYBN) (Cboe CA:CYBN) (“Cybin” or the “Company”), a clinical-stage breakthrough neuropsychiatry company committed to revolutionizing mental healthcare by developing new and innovative next-generation treatment options, is pleased to announce that Doug Drysdale, Cybin’s Chief Executive Officer, will participate in a fireside chat at the Canaccord Genuity 44th Annual Growth Conference, taking place August 13-14, 2024 in Boston, MA. Mr. Drysdale’s fireside chat will be webcast live on Tuesday, August 13, 2024, at 2:00 p.m. ET. To listen to the event, please click here to access the webcast. The archived webcast will also be available on the Company’s investor relations website…

Atai

Press

atai Life Sciences to Participate in the Canaccord Genuity 44th Annual Growth Conference

NEW YORK and BERLIN, Aug. 07, 2024 (GLOBE NEWSWIRE) — atai Life Sciences (NASDAQ: ATAI) (“atai” or “Company”), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, today announced that the Company’s management team is scheduled to participate in the Canaccord Genuity 44th Annual Growth Conference taking place in Boston, MA from August 13-15, 2024. Details of the company’s participation: Format: Fireside chat and 1×1 investor meetingsDate and Time: Fireside chat on Wednesday August 14 at 11:00 A.M. EDTWebcast link: Here An archived replay will be available on the Investors section of the atai website under Events for up to 90 days. About…

Health & Science

Oregon Grants First Psychedelic Edibles Manufacturer License

Oregon has made history by awarding its first-ever psychedelic edibles manufacturer license to Spiritus Oregon, a company based in Milwaukie known for producing psilocybin edibles. This significant milestone marks a new era in the state’s approach to psilocybin, opening doors for innovative therapies and products aimed at enhancing well-being. Spiritus Oregon’s Breakthrough in Psychedelic Edibles Spiritus Oregon, operating under the Horizon Edibles brand, has received recognition for its pioneering efforts in the psilocybin industry. The company’s dark chocolate edibles, infused with homogenized, dried psilocybin mushrooms, promise a nutty, earthy flavor profile, setting a high standard for future products in this…

Clearmind

Press

Clearmind Medicine: New Scientific Publication Shows MEAI’s Potential as a Novel Weight Loss Drug

Vancouver, Canada, Aug. 06, 2024 (GLOBE NEWSWIRE) — Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) (“Clearmind” or the “Company”), a clinical-stage biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solve major under-treated health problems, today announced that a new article published by Baraghithy et al, revealed promising results from a recent study on 5-methoxy-2-aminoindane (MEAI) for combating obesity. The study was meticulously conducted by a team of experts led by Prof. Joseph Tam, head of the Obesity and Metabolism Laboratory at the School of Pharmacy in the Hebrew University of Jerusalem. Key findings from the study include: These findings are based on the results from Clearmind…